Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea

Inclusion Criteria: * Patients with culture-positive stool sample with Campylobacter concisus * Diarrheic patients ≥ 18 years * symptoms of diarrhea defined as three or more watery stools per day or * two watery stools per day + at least one of the following symptoms: abdominal pain, nausea, vomiting or fever. * Diarrheic symptoms for a minimum of 24 hours before enrollment. * Diarrheic symptoms for a maximum of 21 days before enrollment. * Informed oral and signed written consent, with documentation that all relevant information about the study is given to the patient. * The patient must be willing and able to participate in the trial. Exclusion Criteria: * Hypersensitivity to azithromycin, erythromycin, macrolide or other ketolide-antibiotics * Pregnancy or breastfeeding (if relevant). * Culture positive stool sample with a Co-pathogen. * Treatment with other antibiotics (in any stage 21 days before the first stool sample). * Patients with severe liver disease. * Patients with severe renal impairment (GFR \<10 ml / min). * Patients with congenital or documented acquired QT prolongation. * Patients treated with other active drugs that prolong the QT interval such as: antiarrhythmics of classes IA and III, cisapride and terfenadine. * Patients with electrolyte disorders, particularly hypokalemia and hypomagnesemia. * Patients with clinically relevant bradycardia, arrhythmia or severe heart failure. * Inflammatory bowel diseases * Chronic diarrhea of known cause. * Dementia. * Serious illness less than 21 days from the planned entry into the study. * Patients treated with medications that have interactions with azithromycin e.g. alkaloids, ciclosporin or amiodarone. * Patients involved in the planning or execution of the study.